Saturday, 3 October 2026European Markets

Energy Markets

4 articles

2.5 Bcf/d Permian pipeline to boost US Gulf Coast LNG exports by 2029

2.5 Bcf/d Permian pipeline to boost US Gulf Coast LNG exports by 2029

MPLX's Blackcomb Pipeline will add 2.5 billion cubic feet per day of Permian gas to Gulf Coast LNG terminals by end-2028. The connection could increase US LNG available for European buyers as the EU seeks alternatives to pipeline gas imports.

ViaNews Editorial Team (Europe)•
European Natural Gas Prices Surge as Commodities Rally Amid Supply Risks

European Natural Gas Prices Surge as Commodities Rally Amid Supply Risks

European natural gas prices are surging as part of a broader commodities rally driven by macro uncertainty and geopolitical supply concerns. Gold futures hit record highs at $4,200/oz while investors rotate into hard assets amid expectations for Federal Reserve rate cuts. The flight-to-safety movement comes as tech indices end winning streaks and supply risk concerns intensify across energy markets.

ViaNews Editorial Team (Europe)•
European Natural Gas Prices Spike as UK Political Turmoil Compounds Energy Market Volatility

European Natural Gas Prices Spike as UK Political Turmoil Compounds Energy Market Volatility

European natural gas prices surged in late November 2026 amid UK political instability and broader commodity market turbulence. The energy price spike coincided with a flight to safe-haven assets, driving gold futures to record $4,200/oz while Bitcoin dropped 19% for the month. Continental energy markets face mounting uncertainty as macro pressures amplify supply concerns.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com